Ligand Pharmaceuticals (LGND) News Today $112.77 -1.35 (-1.18%) Closing price 04:00 PM EasternExtended Trading$112.77 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Stephens Investment Management Group LLC Sells 5,914 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Stephens Investment Management Group LLC lessened its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 1.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,782 shares of the biotechnology compaFebruary 9 at 7:03 AM | marketbeat.comAnalyzing ESSA Pharma (NASDAQ:EPIX) & Ligand Pharmaceuticals (NASDAQ:LGND)February 8 at 1:21 AM | americanbankingnews.comabrdn plc Sells 72,509 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)abrdn plc trimmed its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 29.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 176,760 shares of the biotechnology company's stockFebruary 7, 2025 | marketbeat.comLigand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 7, 2025 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by AnalystsFebruary 5, 2025 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objFebruary 5, 2025 | marketbeat.comLooking Back On Ligand PharmaceuticalsFebruary 3, 2025 | seekingalpha.comChicago Capital LLC Has $59.10 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Chicago Capital LLC boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 551,588 shares of the bioteFebruary 3, 2025 | marketbeat.comHantz Financial Services Inc. Takes $839,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,827 shares of the biotechnology cFebruary 1, 2025 | marketbeat.comCourt Place Advisors LLC Decreases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Court Place Advisors LLC lessened its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 57.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,783 shares of the biotechnologyJanuary 28, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock Crosses Above 200 Day Moving Average - Here's WhyLigand Pharmaceuticals (NASDAQ:LGND) Shares Cross Above 200 Day Moving Average - Time to Sell?January 25, 2025 | marketbeat.comSimplified redesign of proteins can improve ligand bindingJanuary 22, 2025 | msn.comBurney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Burney Co. lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,520 shares of the biotechnJanuary 17, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co.JPMorgan Chase & Co. trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 11.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 56,451 shares of the biotechnology company's stoJanuary 17, 2025 | marketbeat.comLigand Pharma (LGND) Gets a Buy from Craig-HallumJanuary 14, 2025 | markets.businessinsider.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by BrokeragesShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have been assigned a consensus rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price targJanuary 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Pass Above 200-Day Moving Average - Time to Sell?Ligand Pharmaceuticals (NASDAQ:LGND) Shares Cross Above 200-Day Moving Average - Here's WhyJanuary 8, 2025 | marketbeat.comJane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Jane Street Group LLC cut its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 35.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,452 shares of the biotechnology company'sDecember 28, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock, Guidance And ForecastDecember 27, 2024 | benzinga.comLigand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last yearDecember 27, 2024 | finance.yahoo.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2024 earnings guidance. The company provided EPS guidance of 5.500-5.700 for the period, compared to the consensus estimate of 5.650. The company also issued revenue guidance of $160.0 millionillion-$165.0 millionillion, compared to the consensus estimate of $163.4 millionillion.December 27, 2024 | marketbeat.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells 2,104 Shares of StockDecember 27, 2024 | insidertrades.comInsider Sell Alert: Octavio Espinoza Sells Shares of Ligand Pharmaceuticals Inc (LGND)December 26, 2024 | gurufocus.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 SharesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 2,104 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $116.37, for a total value of $244,842.48. Following the completion of the transaction, the chief financial officer now owns 20,647 shares in the company, valued at approximately $2,402,691.39. The trade was a 9.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 26, 2024 | marketbeat.comGeode Capital Management LLC Acquires 22,495 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Geode Capital Management LLC raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 428,270 shares of the bioDecember 24, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)December 23, 2024 | markets.businessinsider.comBenchmark Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND)Benchmark restated a "buy" rating and issued a $135.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday.December 23, 2024 | marketbeat.comFranklin Resources Inc. Has $9.79 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Franklin Resources Inc. boosted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 503.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 94,659 shares of the biotechnology company's stock after buying an additionalDecember 22, 2024 | marketbeat.comBarclays PLC Has $4.35 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Barclays PLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,456 shares of theDecember 22, 2024 | marketbeat.comWellington Management Group LLP Trims Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Wellington Management Group LLP trimmed its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 39.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 8,688 shares of the biotechnology company's stock after selling 5,714 shares duriDecember 20, 2024 | marketbeat.comZacks Small Cap Has Bullish Outlook for LGND FY2025 EarningsLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Zacks Small Cap lifted their FY2025 earnings estimates for Ligand Pharmaceuticals in a research report issued on Monday, December 16th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biotechnology company will posDecember 18, 2024 | marketbeat.comState Street Corp Boosts Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)State Street Corp boosted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 707,414 shares of the biotechnology coDecember 18, 2024 | marketbeat.comZacks Small Cap Has Strong Estimate for LGND FY2026 EarningsLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Stock analysts at Zacks Small Cap lifted their FY2026 earnings estimates for Ligand Pharmaceuticals in a research report issued to clients and investors on Monday, December 16th. Zacks Small Cap analyst J. Vandermosten now anticipaDecember 17, 2024 | marketbeat.comFmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Fmr LLC lifted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 550.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,749 shares of the biotechnology company's stock after pDecember 17, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from AnalystsShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price oDecember 17, 2024 | marketbeat.comLigand price target raised to $160 from $150 at BarclaysDecember 16, 2024 | markets.businessinsider.comLGND: 2025 View Calls for 17% Topline GrowthDecember 16, 2024 | msn.comBarclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00Barclays increased their price target on shares of Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday.December 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Walgreens Boots Alliance (WBA)December 16, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for LGND FY2025 Earnings?Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Ligand Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnolDecember 13, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Decreased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 13.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutioDecember 13, 2024 | marketbeat.comLigand Pharma Poised for Growth: Analyst Recommends Buy on Strategic Investments and Revenue ProjectionsDecember 12, 2024 | markets.businessinsider.comCraig-Hallum Releases a Buy Rating on Ligand Pharma (LGND)December 11, 2024 | markets.businessinsider.comLigand Pharma (LGND) Receives a Buy from OppenheimerDecember 11, 2024 | markets.businessinsider.comLigand Pharmaceuticals' (LGND) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating on shares of Ligand Pharmaceuticals in a research report on Wednesday.December 11, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.030. The company also issued revenue guidance of $180.0 millionillion-$200.0 millionillion, compared to the consensus estimate of $183.1 millionillion.December 11, 2024 | marketbeat.comLigand provides updated five-year outlookDecember 11, 2024 | markets.businessinsider.comLigand backs FY24 adjusted EPS view $5.50-$5.70, consensus $5.65December 11, 2024 | markets.businessinsider.comLigand Hosts 2024 Investor and Analyst Day and Introduces 2025 GuidanceDecember 11, 2024 | finance.yahoo.com5,961 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Purchased by Verition Fund Management LLCVerition Fund Management LLC acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,961 shares of the bioteDecember 11, 2024 | marketbeat.com Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼0.710.53▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼65▲LGND Articles Average Week Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News Today MDGL News Today HALO News Today ALKS News Today IONS News Today FOLD News Today BCRX News Today DVAX News Today GERN News Today MNKD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 2/11/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
